Clinical Trial

Assess Safety and Efficacy of VAD044 in HHT Patients

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Part I: The purpose of this Phase 1b proof of concept study, randomised, placebo controlled, double blind, multicentre study is to asssess safety and efficacy of 2 doses of VAD044 in adult HHT patients. Part II: The purpose of this open-label extension following the completion of the randomised double blind treatment and follow-up period (Part I of the study) is to assess the long-term safetty, tolerability and efficacy of VAD044 in adult HHT patients.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-06-01; most recent amendment 2026-03-12.
Status change: Recruiting → Active, Not Recruiting 2025-01-29
Status change: Not Yet Recruiting → Recruiting 2022-09-19
Trial Details
NCT Number NCT05406362
Lead Sponsor Vaderis Therapeutics AG
Conditions Hereditary Hemorrhagic Telangiectasia (HHT)
Enrollment 75 participants
Start Date 2022-07-18
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-17